VEGFA and neoplasm: These include fragmented antibodies such as ranibizumab, antibodies that bind and inhibit VEGF receptors such as ramucirumab, soluble small molecule decoys such as aflibercept, and small molecule tyrosine kinase inhibitors that inhibit VEGF in addition to other tumor-related growth factors, such as sorafenib, sunitinib, pazopanib, axitinib, and regorafenib [132].